IRB# 19384
PHASE 3
Efficacy and Safety Study of Patidegib Topical Gel, 2%, for the Reduction of Disease Burden of Persistently Developing Basal Cell Carcinomas (BCCs) in Subjects with Basal Cell Nevus Syndrome

Non-Melanoma

Please refer to Phase I studies for more clinical trial opportunities and to the Melanoma flowsheet for Melanoma related studies.

Squamous cell carcinoma (SCC)
Basal Cell Carcinoma (BCC)
Other types

Observational

PHASE 2
No studies available

PHASE 3/4
No studies available

IRB#19384 PHASE 3 Efficacy and Safety Study of Patidegib Topical Gel, 2%, for the Reduction of Disease Burden of Persistently Developing Basal Cell Carcinomas (BCCs) in Subjects with Basal Cell Nevus Syndrome

http://www.ohsu.edu/research/rda/so/knight.php

14 JAN 2019